JAMP POSACONAZOLE SUSPENSION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Compra

Scarica Scheda tecnica (SPC)
30-08-2022

Principio attivo:

POSACONAZOLE

Commercializzato da:

JAMP PHARMA CORPORATION

Codice ATC:

J02AC04

INN (Nome Internazionale):

POSACONAZOLE

Dosaggio:

40MG

Forma farmaceutica:

SUSPENSION

Composizione:

POSACONAZOLE 40MG

Via di somministrazione:

ORAL

Confezione:

15G/50G

Tipo di ricetta:

Prescription

Dettagli prodotto:

Active ingredient group (AIG) number: 0152201001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2022-09-02

Scheda tecnica

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
JAMP POSACONAZOLE
posaconazole
Suspension, 40 mg / mL, Oral
Antifungal Agent
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
August 30, 2022
Submission Control Number: 248523
Product Monograph
_JAMP Posaconazole (posaconzole oral suspension)_
Page 2 of 57
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES ...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
.............................................................................................................
5
1.1
Pediatrics
..................................................................................................................
5
1.2
Geriatrics
..................................................................................................................
5
2
CONTRAINDICATIONS
................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 6
4
DOSAGE AND
ADMINISTRATION .................................................................................
6
4.1
Dosing Considerations
..............................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
......................................................... 7
4.4
Administration
..........................................................................................................
8
4.5
Missed Dose
.............................................................
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Scheda tecnica Scheda tecnica francese 30-08-2022

Cerca alert relativi a questo prodotto